Edition:
India

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

6.68USD
9:17pm IST
Change (% chg)

$0.32 (+5.12%)
Prev Close
$6.35
Open
$6.30
Day's High
$6.78
Day's Low
$6.30
Volume
30,843
Avg. Vol
35,880
52-wk High
$8.25
52-wk Low
$3.20

Chart for

About

Arbutus Biopharma Corp is a Canada-based company engaged in biopharmaceutical sector. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company is focused on a process of... (more)
No analyst recommendations are available for .

Overall

Beta: 0.72
Market Cap(Mil.): $493.14
Shares Outstanding(Mil.): 55.03
Dividend: --
Yield (%): --

Financials

  ABUS.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -2.15 -- --
ROI: -51.57 14.84 14.38
ROE: -55.72 16.34 16.07

BRIEF-Arbutus Announces Corporate Update

* ARBUTUS ANNOUNCES CORPORATE UPDATE AND YEAR-END 2017 FINANCIAL RESULTS

15 Mar 2018

BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology

* ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY

23 Feb 2018

BRIEF-Arbutus Enters Exclusivity Agreement With Roivant Sciences

* ARBUTUS ENTERS EXCLUSIVITY AGREEMENT WITH ROIVANT SCIENCES Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

15 Feb 2018

BRIEF-Arbutus Announces Departure Of CFO Bruce Cousins

* ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO

14 Feb 2018

BRIEF-Arbutus Consolidates HBV Business Around Warminster, PA Site

* ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA

08 Feb 2018

Earnings vs. Estimates